Skip to content

Effects of Active Upper-Limb Exoskeleton Training in Simulated Hyper-Gravity on Fine Motor Performance, Brain-Muscle Connectivity, Cardiovascular System and Stress Responses in Real Hyper-Gravity

Effects of Active Upper-Limb Exoskeleton Training in Simulated Hyper-Gravity on Fine Motor Performance, Brain-Muscle Connectivity, Cardiovascular System and Stress Responses in Real Hyper-Gravity: the EGOS Pilot Study.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07278245
Acronym
EGOS
Enrollment
12
Registered
2025-12-12
Start date
2025-10-27
Completion date
2026-01-27
Last updated
2026-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Motor Learning and Physiological Adaptation

Brief summary

The aim of the study presented here is to assess the effects of exoskeleton training on performance in a real hypergravity situation. In particular, it will analyze fine motor control, autonomic nervous system regulation and metabolic responses. To this end, the study will compare two groups during a pointing exercise in a centrifuge (hypergravity). One group will have been trained to do this exercise using an exoskeleton, while the other will have been familiarized with the task without the exoskeleton. It will assess whether the exoskeleton can be an effective and accessible training tool for astronauts.

Interventions

OTHERTraining with an exoskeleton

Training to perform an aiming task under simulated hypergravity via an exoskeleton

Sponsors

Centre National d'Etudes Spatiales
Lead SponsorOTHER_GOV
MEDES Institut de Médecine et de Physiologie Spatiales, Toulouse
CollaboratorUNKNOWN

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Maximum weight of 90 kg * Maximum sitting butt-to-shoulder distance of 70 cm * Certified as healthy by a comprehensive clinical assessment * Normal or corrected to normal vision * Right-handed tested with Edinburgh-Handedness-Inventory-Test (≥6th percentile, on https://www.brainmapping.org/shared/Edinburgh.php) * Non smokers * No alcohol or drug dependence, no medical treatment on a regular basis * Affiliated to a Social Security system and, for non-French resident, holding a European Health Insurance Card (EHIC) or a Global Health Insurance Card (GHIC). * Free of any engagement during the study * Test subjects must be able to understand and speak English * Who agreed to take part in the study and signed the informed consent

Exclusion criteria

* Left-handed tested with Edinburgh-Handedness-Inventory-Test (\<6th percentile) * Subjects with experience in experiments on a short arm human centrifuge or under real hyper-gravity * Non-tolerance to the centrifugation * Any history or presence of clinically relevant chronic disease * Refusal to give permission to contact his general practitioner, * Subject who, in the judgment of the investigator, is likely to be non-compliant during the study, or unable to cooperate because of a language problem or poor mental development, * Subject in the exclusion period of a clinical research, * Subject who has received more than 6000 Euros within 12 months for being a research subject, * Subject who cannot be contacted in case of emergency, * Vulnerable people according to law "Code de la Santé Publique" (L1121-5 to L1121-8)

Design outcomes

Primary

MeasureTime frameDescription
Task performance (movement accuracy)From familiarisation sessions (Day 1 to Day 4) to testing day at Day 5.Task performance (movement accuracy) is defined as the difference between the position touched on the screen and the position of the displayed target. The participants will be required to perform an aiming movement task using their right arm, directed toward a target.The participants will need to point to the center of the displayed target.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026